Clinical trials: AIHA - Warm Autoimmune Hemolytic Anemia
- Condition AIHA - Warm Autoimmune Hemolytic Anemia
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Warm Autoimmune Hemolytic Anemia
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
The purpose of this post-trial access (PTA) program is to provide nipocalimab for the treatment of participants with Warm Autoimmune Hemolytic Anemia (wAIHA) who are experiencing clinical benefit after completing 28-weeks…
- Trial name
- NCT05221619
- Testing
- Nipocalimab
- Sponsor
- Janssen Research & Development, LLC